ORPHA:329931
C3 glomerulonephritis
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
1,230
Trials
10
Interventional, condition-specific
Researchers
1,354
Distinct authors in sample
Gene link
C3, CFB, CFH
Definitive
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A histological subtype of C3 glomerulopathy characterized by C3 deposition in renal tissue in the absence or near-absence of immunoglobulin deposits, in a patient with the classic clinical features of glomerulonephritis and the electron microscopic findings of predominant subendothelial, occasionally subepithelial (so-called ''humps''), and intramembranous deposits, but without the typical electron-dense deposits of dense deposit disease.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0013892
- OMIM:614809
- UMLS:C4055342
- NCIT:C123043
Additional Mondo synonyms (2)
complement-mediated membranoproliferative glomerulonephritis · nephropathy due to CFHR5 deficiency
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — C3, CFB, CFH, CFHR5, CFI
- LiteraturePresent
1,230 matched papers (946 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
10 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (C3, CFB, CFH…).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
1,230
1,230 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
1,230 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
946 in the last 10 years · low confidence
Phrase hits: 1,230 · MeSH hits: 0
Who's working on it?
1,354
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Caravaca-Fontán F7 papers · 2026
Department of Nephrology, Research Institute Hospital 12 de Octubre (imas12), Madrid, Spain.
Papers in Europe PMC - 02Praga M6 papers · 2026
Department of Medicine, Complutense University, Madrid, Spain.
Papers in Europe PMC - 03Sethi S6 papers · 2026
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Papers in Europe PMC - 04Fervenza FC4 papers · 2026
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
Papers in Europe PMC - 05Emma F3 papers · 2025
Division of Nephrology, Bambino Gesù Children's Hospital - IRCCS, Rome, Italy.
Papers in Europe PMC - 06Lee H3 papers · 2025
Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Papers in Europe PMC - 07Nagano C3 papers · 2025
Department of Pediatrics, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-Cho, Chuo-Ku, Kobe, 650-0017, Japan.
Papers in Europe PMC - 08Nozu K3 papers · 2025
Department of Pediatrics, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-Cho, Chuo-Ku, Kobe, 650-0017, Japan.
Papers in Europe PMC - 09Ohashi K3 papers · 2026
Department of Human Pathology, Tokyo Medical and Dental University, Tokyo.
Papers in Europe PMC - 10Sawai T3 papers · 2025
Department of Pediatrics, Shiga University of Medical Science, Otsu, Japan.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
10
interventional trials for this specific condition
10 interventional trials matched this specific condition name; 1 currently recruiting in our sample.
Data as of 27 July 2026
10 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 91.7th percentile).
low confidence · 91.7th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
10 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT04183101·RECRUITING·Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy
Conditions: C3 Glomerulopathy · Membranoproliferative Glomerulonephritis · Complement Abnormality · Dense Deposit Disease·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"C3 glomerulonephritis" OR "complement-mediated membranoproliferative glomerulonephritis" OR "nephropathy due to CFHR5 deficiency"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"C3 glomerulonephritis" OR "complement-mediated membranoproliferative glomerulonephritis" OR "nephropathy due to CFHR5 deficiency" OR "C3" OR "CFB" OR "CFH"
Recall-expansion terms: C3, CFB, CFH
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 10 interventional · 0 observational · 1 expanded access. Only interventional studies enter the trial headline.
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1230) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T13:57:24.339Z